Barclays PLC Increases Stock Holdings in AxoGen, Inc. (NASDAQ:AXGN)

Barclays PLC lifted its stake in shares of AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 119.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 72,036 shares of the medical equipment provider's stock after acquiring an additional 39,182 shares during the quarter. Barclays PLC owned 0.16% of AxoGen worth $1,010,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of AXGN. First Light Asset Management LLC lifted its stake in AxoGen by 336.6% in the second quarter. First Light Asset Management LLC now owns 3,344,033 shares of the medical equipment provider's stock worth $24,211,000 after acquiring an additional 2,578,147 shares during the last quarter. Divisadero Street Capital Management LP raised its holdings in shares of AxoGen by 587.2% in the 2nd quarter. Divisadero Street Capital Management LP now owns 686,994 shares of the medical equipment provider's stock valued at $4,974,000 after purchasing an additional 587,024 shares in the last quarter. Parkman Healthcare Partners LLC purchased a new stake in shares of AxoGen during the 3rd quarter worth $5,789,000. FMR LLC lifted its position in shares of AxoGen by 743.1% during the 3rd quarter. FMR LLC now owns 178,957 shares of the medical equipment provider's stock worth $2,509,000 after purchasing an additional 157,730 shares during the last quarter. Finally, Eagle Asset Management Inc. acquired a new position in shares of AxoGen during the third quarter worth $1,728,000. 80.29% of the stock is currently owned by institutional investors and hedge funds.

AxoGen Stock Down 0.1 %

Shares of NASDAQ:AXGN traded down $0.01 during trading on Tuesday, hitting $16.48. 589,798 shares of the company were exchanged, compared to its average volume of 392,300. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. The firm's 50 day moving average price is $14.25 and its 200-day moving average price is $12.17. The stock has a market capitalization of $725.25 million, a P/E ratio of -51.50 and a beta of 1.06. AxoGen, Inc. has a 12-month low of $5.55 and a 12-month high of $17.23.

Analyst Ratings Changes

Separately, StockNews.com upgraded AxoGen from a "hold" rating to a "buy" rating in a research note on Tuesday, October 15th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $15.00.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.